Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Multiple Sclerosis

Free Subscription Articles published in J Neuroimmunol Retrieve available abstracts of 112 articles: HTML format

Single Articles

July 2026
1. BAYDAR C, Yilgor A
   Coordinated oxidative shift during relapse and recovery in multiple sclerosis: A paired analysis of multiple biomarkers.
   J Neuroimmunol. 2026;420:579030.
   PubMed     Abstract available
   
   
   June 2026
2. GLUSCEVIC S, Koc ER, Klisic A, Ziemssen T, et al
   Peripheral redox biomarkers in multiple sclerosis: associations with phenotype, cognition, and fatigue.
   J Neuroimmunol. 2026;419:579018.
   PubMed     Abstract available
   
   
   
3. LOPES LMF, Hygino J, Cafasso MOS, Sacramento PM, et al
   Absence of PD-1 expression on T(FH) and T(FC) cell subsets correlates with severity of multiple sclerosis.
   J Neuroimmunol. 2026;419:579012.
   PubMed     Abstract available
   
   
   
4. ABDULRIDHA GAO, Fadhel AS, Al-Kinany SQ, Makki NF, et al
   Serum IDO1 and beta-catenin levels in patients with multiple sclerosis with and without atherosclerosis: A case-control study.
   J Neuroimmunol. 2026;419:579013.
   PubMed     Abstract available
   
   
   May 2026
5. LI V, Pandey K, Binder MD, Reid HH, et al
   Identification of an immunogenic epitope from RASGRP2 with specificity for HLA-DR15 in multiple sclerosis.
   J Neuroimmunol. 2026;418:578971.
   PubMed     Abstract available
   
   
   April 2026
6. PLESA A, Maruntelu I, Sirbu OM, Constantinescu I, et al
   MicroRNA profiles in multiple sclerosis: A review of the literature.
   J Neuroimmunol. 2026;417:578946.
   PubMed     Abstract available
   
   
   
7. KHEDR EM, Haridy NA, El-Deen HB, Abdelwarith A, et al
   Tracking the invisible: Impact of disease-modifying therapies on serum neurofilament light chain and clinical outcomes in treatment-naive multiple sclerosis.
   J Neuroimmunol. 2026;417:578928.
   PubMed     Abstract available
   
   
   March 2026
8. ATASEVER U
   Bile acid-microbiota interactions in multiple sclerosis: From experimental models to early clinical evidence.
   J Neuroimmunol. 2026;415:578898.
   PubMed     Abstract available
   
   
   February 2026
9. DAMSBO K, Reyahi A, Nik AM, Oubounyt M, et al
   Astrocyte-specific FoxF2 modulates immune and myelin repair: Evidence from multiple sclerosis lesions and an animal model.
   J Neuroimmunol. 2026;415:578896.
   PubMed     Abstract available
   
   
   
10. BENKHOUCHA M, Breville G, Senoner I, Chliate S, et al
    Soluble c-Met correlates with NfL and GFAP levels in the CSF of patients with multiple sclerosis.
    J Neuroimmunol. 2026;415:578895.
    PubMed    
    
    
    
11. BUNGANIC R, Revendova KZ, Hradilek P, Kusnierova P, et al
    Comparison of SIMOA and VEUS technologies for serum glial fibrillary acidic protein measurement.
    J Neuroimmunol. 2026;411:578825.
    PubMed     Abstract available
    
    
    January 2026
12. OSTROVSKY A, Simon AJ, Kaplan B
    Free light chains analysis in cerebrospinal fluid for the diagnosis of multiple sclerosis: A study in the Israeli population.
    J Neuroimmunol. 2026;413:578873.
    PubMed     Abstract available
    
    
    
13. BIANCO A, Russo R, Cicia A, Marini S, et al
    Wash-out duration and lymphocyte count in switching from fingolimod to ofatumumab: A case report and literature review.
    J Neuroimmunol. 2026;410:578808.
    PubMed     Abstract available
    
    
    
14. RANIERI G, Chiarugi A, Buonvicino D
    Early exposure of NOD/ShiLtJ mice to Freund's adjuvant prompts delayed, spontaneous progressive encephalomyelitis.
    J Neuroimmunol. 2026;410:578809.
    PubMed     Abstract available
    
    
    
15. PALMER AL, Wang R, Zonta YR, Bailey ZDJ, et al
    Cytokine and chemokine production by astrocytes is influenced by Cystatin C.
    J Neuroimmunol. 2026;410:578801.
    PubMed     Abstract available
    
    
    
16. ALEXAKI A, Baltoumas F, Tzanetakos D, Zografou C, et al
    B cell tolerance checkpoint function in multiple sclerosis and transient CD52 depletion.
    J Neuroimmunol. 2026;413:578854.
    PubMed     Abstract available
    
    
    December 2025
17. ABDELGAIED MY, Abdelgawad O, Rashad MH, Solayman MH, et al
    Efficacy and tolerability of metformin as an adjuvant therapy in patients with relapse-remitting multiple sclerosis receiving interferon Beta 1a: A randomized pilot trial.
    J Neuroimmunol. 2025;412:578852.
    PubMed     Abstract available
    
    
    
18. ULUC F, Ceylan D, Turkoglu SA
    Pilot analysis of Chitinase-3-like protein 1 and soluble Syndecan-1 CSF levels as potential biomarkers in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2025;411:578836.
    PubMed     Abstract available
    
    
    November 2025
19. OREFICE NS, Amoriello R, Maghrebi O, Ballerini C, et al
    Early response in cytokine and miR-124a, -125b, -223 expression to anti-CD20 in Multiple Sclerosis and its animal model - a preliminary analysis.
    J Neuroimmunol. 2025;411:578823.
    PubMed     Abstract available
    
    
    
20. MIYAZAKI Y, Yokote H, Fujimori J, Sakurai K, et al
    Wearable-based physiological monitoring and brain magnetic resonance imaging metrics in multiple sclerosis: A feasibility study.
    J Neuroimmunol. 2025;410:578819.
    PubMed     Abstract available
    
    
    October 2025
21. DAGHLAS I, Pluvinage JV, Gill D
    Genetically reduced MTHFR activity confers protection against multiple sclerosis.
    J Neuroimmunol. 2025;410:578784.
    PubMed     Abstract available
    
    
    
22. DITLEVSEN REGEN E, Victor D, Hendrikx T
    Neoehrlichiosis in patients with multiple sclerosis in Halmstad, Sweden: A case series.
    J Neuroimmunol. 2025;410:578787.
    PubMed     Abstract available
    
    
    
23. NATHOO N, Neyal N, Son J, Schwarz CG, et al
    The hidden toll: Atrophy of key central nervous system relays in African American women with multiple sclerosis.
    J Neuroimmunol. 2025;409:578776.
    PubMed     Abstract available
    
    
    September 2025
24. GOUZOUASIS V, Tsifintaris M, Tastsoglou S, Markoglou N, et al
    Epstein-Barr virus reactivation is associated with altered immune cell profiles in peripheral blood and cerebrospinal fluid of treatment-naive multiple sclerosis patients.
    J Neuroimmunol. 2025;409:578758.
    PubMed     Abstract available
    
    
    
25. HANSEN MM, El Mahdaoui S, Hansen MB, Hvalkof VH, et al
    Mononuclear phagocytes in blood and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis: Untreated and treated with anti-CD20 therapy.
    J Neuroimmunol. 2025;409:578751.
    PubMed     Abstract available
    
    
    August 2025
26. TANG Y, Wang H, Wang X, Yan Z, et al
    Characterizing the relationship between FLAIR hyper-rim lesions and paramagnetic rim lesions in multiple sclerosis.
    J Neuroimmunol. 2025;408:578738.
    PubMed     Abstract available
    
    
    
27. BICIMVEREN MS, Ciftci SN, Alp G
    A rare cause of visual impairment in patients with multiple sclerosis: Uveitis.
    J Neuroimmunol. 2025;407:578714.
    PubMed     Abstract available
    
    
    July 2025
28. YANG C, Jiang X, Cheng Z, Zheng C, et al
    Neuroprotective effects of Analgecine by modifying cholesterol metabolism in EAE mice model of multiple sclerosis.
    J Neuroimmunol. 2025;407:578704.
    PubMed     Abstract available
    
    
    
29. SAXENA S, Zhirova A, Krishnan R, Healy B, et al
    SARS-CoV-2 spike antibody and T cell response in MS patients on high efficacy therapies post vaccine.
    J Neuroimmunol. 2025;407:578694.
    PubMed     Abstract available
    
    
    
30. AKOWUAH PK, Botchway E, Owusu E, Ohene DA, et al
    Are corneal nerve and dendritic cell parameters assessed via corneal confocal microscopy good markers for multiple sclerosis? - A systematic review and meta-analysis.
    J Neuroimmunol. 2025;407:578697.
    PubMed     Abstract available
    
    
    
31. GOMEZ FP, Bake S, Young CR, Sohrabji F, et al
    Therapeutic effects of estrogens on inflammatory demyelination in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2025;407:578698.
    PubMed     Abstract available
    
    
    
32. KAUR G, Kumari P, Devi P, Swaminathan A, et al
    Gut dysbiosis influences the pathophysiology of multiple sclerosis: A case-control study from North India.
    J Neuroimmunol. 2025;407:578696.
    PubMed     Abstract available
    
    
    June 2025
33. WELSH NC, DiSano KD, Pike SC, Linzey M, et al
    Network analysis of intrathecally synthesized proteins to unravel mechanisms of disease course in multiple sclerosis.
    J Neuroimmunol. 2025;406:578678.
    PubMed     Abstract available
    
    
    
34. NASEER MA, Hegazy M, El-Mehdawy KM, Ashraf H, et al
    Serum levels of tumor necrosis factor and TNFRSF1A gene polymorphisms in Egyptian multiple sclerosis patients: the influence on susceptibility and severity.
    J Neuroimmunol. 2025;406:578672.
    PubMed     Abstract available
    
    
    
35. ZIVOTIC I, Kolic I, Stefanovic M, Stefanovic NM, et al
    Association of TGFB1 and IFNB1 expression levels in peripheral blood mononuclear cells with multiple sclerosis with respect to proximal rs1800469 and rs2275888 eQTLs.
    J Neuroimmunol. 2025;406:578666.
    PubMed     Abstract available
    
    
    April 2025
36. DEFFENBAUGH JL, Jung KJ, Murphy SP, Liu Y, et al
    Corrigendum to "Novel model of multiple sclerosis induced by EBV-like virus generate a unique B cell population" [Journal of Neuroimmunology volume 394 (2024) 578408].
    J Neuroimmunol. 2025;404:578625.
    PubMed    
    
    
    
37. MASI F, Al Qudsi S, Visigalli D, Zardini E, et al
    Oligoclonal IgM band patterns in multiple sclerosis: A two-center study.
    J Neuroimmunol. 2025;404:578622.
    PubMed     Abstract available
    
    
    
38. EL MAHDAOUI S, Husted SR, Hansen MB, Cobanovic S, et al
    Corrigendum to "Cerebrospinal fluid soluble CD27 is associated with CD8+ T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis" [Journal of neuroimmunology vol. 381 (2023): 578128].
    J Neuroimmunol. 2025;403:578607.
    PubMed    
    
    
    
39. PETROU P, Kassis I, Levi Y, Yaghmour N, et al
    Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01).
    J Neuroimmunol. 2025;403:578613.
    PubMed     Abstract available
    
    
    
40. MARQUES RF, Pedrosa DA, Talim N, Lemos JC, et al
    Relapsing-remitting multiple sclerosis as a potential consequence of thalidomide treatment: A case report.
    J Neuroimmunol. 2025;404:578606.
    PubMed     Abstract available
    
    
    March 2025
41. ZEYDAN B, Neyal N, Nathoo N, Rangachari M, et al
    Effects of androgen modifying therapies on disease activity in older men with multiple sclerosis.
    J Neuroimmunol. 2025;403:578589.
    PubMed     Abstract available
    
    
    
42. CHUANG TY, LaBarre BA, Corbali O, Healy BC, et al
    Endocrine disrupting chemicals in early MS disease activity.
    J Neuroimmunol. 2025;400:578546.
    PubMed     Abstract available
    
    
    February 2025
43. KHEDR EM, Hassan MM, Ezzeldeen MY, El-Kady MS, et al
    Motor symptoms at onset and manual dexterity predict cognitive impairment in drug-naive individuals with multiple sclerosis.
    J Neuroimmunol. 2025;401:578571.
    PubMed     Abstract available
    
    
    
44. YAN Z, Yang X, Lin B, Zhu Q, et al
    Brain network alteration was associated with 'no evidence of disease activity' status in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2025;400:578549.
    PubMed     Abstract available
    
    
    
45. CULINA S, Commere PH, Turc E, Jouy A, et al
    MicroRNA signatures of CD4(+) T cell subsets in healthy and multiple sclerosis subjects determined by small RNA-sequencing.
    J Neuroimmunol. 2025;401:578531.
    PubMed     Abstract available
    
    
    January 2025
46. RANDHAWA G, Mobarakabadi M, D'Mello C, Morch MT, et al
    Targeting extracellular matrix components to attenuate microglia neuroinflammation: A study of fibulin-2 and CSPGs in a model of multiple sclerosis.
    J Neuroimmunol. 2025;400:578533.
    PubMed     Abstract available
    
    
    
47. ETEMADIFAR M, Aghili A, Shojaei S, Alaei SA, et al
    Balo concentric sclerosis, an emerging variant of multiple sclerosis: A case-series and literature review.
    J Neuroimmunol. 2025;400:578527.
    PubMed     Abstract available
    
    
    
48. GULEC B, Everest E, Uygunoglu U
    Letter to the Editor Regarding "Spinocerebellar ataxia masquerading as multiple sclerosis, a case report".
    J Neuroimmunol. 2025;399:578523.
    PubMed    
    
    
    December 2024
49. GURSKI CJ, Hajiyeva Z, Veltri AJ, Fenton K, et al
    Corrigendum to "Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels are B cell depletion with Ocrelizumab" [J. Neuroimmunol. 339:578502 (2024)].
    J Neuroimmunol. 2024;399:578519.
    PubMed    
    
    
    
50. LIANG Y, Huang J, Zhang X, Xu F, et al
    Quantitative assessment of thalamic damage and serum neurofilament light chain in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2024;399:578504.
    PubMed     Abstract available
    
    
    
51. GURSKI CJ, Hajiyeva Z, Veltri AJ, Fenton K, et al
    Elevated frequencies of activated memory B cells in multiple sclerosis are reset to healthy control levels after B cell depletion with Ocrelizumab.
    J Neuroimmunol. 2024;399:578502.
    PubMed     Abstract available
    
    
    November 2024
52. OZKOSAR A, Oktelik FB, Gelmez MY, Ozturk Erden S, et al
    Retinoic acid modulates peripheral blood helper innate lymphoid cell composition in vitro in patients with multiple sclerosis.
    J Neuroimmunol. 2024;398:578489.
    PubMed     Abstract available
    
    
    September 2024
53. BAI G, Bai Y, Guan H, Ren H, et al
    A case report of lymphoproliferative disease in brain following therapies with mycophenolate Mofetil and Fingolimod and literature review.
    J Neuroimmunol. 2024;394:578410.
    PubMed     Abstract available
    
    
    
54. XU Y, Wei Y, Shi Z, Yin F, et al
    Multimodal magnetic resonance longitudinal study on the deep gray matter in multiple sclerosis patients with teriflunomide.
    J Neuroimmunol. 2024;396:578445.
    PubMed     Abstract available
    
    
    August 2024
55. ABOSEIF A, Amin M, Macaron G, Ontaneda D, et al
    Discordance of reported multiple sclerosis clinical course amongst patients and providers.
    J Neuroimmunol. 2024;395:578443.
    PubMed     Abstract available
    
    
    
56. BILEK F, Ercan Z, Deniz G, Ozgul S, et al
    High-intensity intermittent exercise increases serum levels of chitinase 3-like protein-1 and matrix metalloproteinase-9 in persons with multiple sclerosis.
    J Neuroimmunol. 2024;395:578434.
    PubMed     Abstract available
    
    
    
57. KRIEGER S, Zarif M, Bumstead B, Buhse M, et al
    Evaluating the effect of dimethyl fumarate on subclinical biomarkers in a real-world patient cohort.
    J Neuroimmunol. 2024;393:578397.
    PubMed     Abstract available
    
    
    
58. LEHIKOINEN J, Strandin T, Parantainen J, Nurmi K, et al
    Fibrinolysis associated proteins and lipopolysaccharide bioactivity in plasma and cerebrospinal fluid in multiple sclerosis.
    J Neuroimmunol. 2024;395:578432.
    PubMed     Abstract available
    
    
    
59. ETEMADIFAR M, Alaei SA, Sedaghat N, Ghandehari AH, et al
    TEMPORARY REMOVAL: Pure spinal multiple sclerosis: A case series of a possible new entity.
    J Neuroimmunol. 2024 Aug 8:578429. doi: 10.1016/j.jneuroim.2024.578429.
    PubMed    
    
    
    
60. TORTOSA-CARRERES J, Cubas-Nunez L, Piqueras M, Castillo-Villalba J, et al
    Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
    J Neuroimmunol. 2024;394:578428.
    PubMed     Abstract available
    
    
    July 2024
61. WUERCH EC, Mirzaei R, Yong VW
    Niacin produces an inconsistent treatment response in the EAE model of multiple sclerosis.
    J Neuroimmunol. 2024;394:578421.
    PubMed     Abstract available
    
    
    
62. DEFFENBAUGH JL, Jung KJ, Murphy SP, Liu Y, et al
    Novel model of multiple sclerosis induced by EBV-like virus generates a unique B cell population.
    J Neuroimmunol. 2024;394:578408.
    PubMed     Abstract available
    
    
    
63. YOKOTE H, Miyazaki Y, Fujimori J, Nishida Y, et al
    Characterization of Japanese multiple sclerosis patients with progression independent of relapse activity: A 2-year multicenter cohort study.
    J Neuroimmunol. 2024;394:578407.
    PubMed     Abstract available
    
    
    June 2024
64. RECHTMAN A, Zveik O, Haham N, Brill L, et al
    A protective effect of lower MHC-II expression in MOGAD.
    J Neuroimmunol. 2024;391:578351.
    PubMed     Abstract available
    
    
    
65. WHEELER D, Bezih M, Lannen N
    Spinocerebellar ataxia masquerading as multiple sclerosis, a case report.
    J Neuroimmunol. 2024;393:578385.
    PubMed    
    
    
    
66. YONG HYF, Batty NJ, Tottenham I, Koch M, et al
    Soluble adhesion molecules: Cognitive worsening biomarkers in primary progressive multiple sclerosis?
    J Neuroimmunol. 2024;393:578384.
    PubMed    
    
    
    May 2024
67. SRIRAM S, Kim KW, Ljunggren-Rose A
    Targeted DeSUMOylation as a therapeutic strategy for multiple sclerosis.
    J Neuroimmunol. 2024;392:578371.
    PubMed     Abstract available
    
    
    
68. GELIBTER S, Saraceno L, Pirro F, Susani EL, et al
    As time goes by: Treatment challenges in elderly people with multiple sclerosis.
    J Neuroimmunol. 2024;391:578368.
    PubMed     Abstract available
    
    
    April 2024
69. LI S, Sun D, Wang R, Du Q, et al
    Causal association between multiple sclerosis and severe COVID-19: A bidirectional Mendelian randomization study.
    J Neuroimmunol. 2024;391:578352.
    PubMed    
    
    
    
70. LI V, Binder MD, Purcell AW, Kilpatrick TJ, et al
    Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for multiple sclerosis.
    J Neuroimmunol. 2024;390:578347.
    PubMed     Abstract available
    
    
    
71. MUNZ C
    Altered EBV specific immune control in multiple sclerosis.
    J Neuroimmunol. 2024;390:578343.
    PubMed     Abstract available
    
    
    March 2024
72. HAHAM N, Zveik O, Rechtman A, Brill L, et al
    Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD.
    J Neuroimmunol. 2024;388:578289.
    PubMed     Abstract available
    
    
    
73. CHANG EH, Hardy TA
    Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
    J Neuroimmunol. 2024;389:578330.
    PubMed     Abstract available
    
    
    
74. FOGEL A, Olcer M, Goel A, Feng X, et al
    Novel biomarkers and interferon signature in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2024;389:578328.
    PubMed     Abstract available
    
    
    February 2024
75. SRIWASTAVA S, Elkhooly M, Amatya S, Shrestha K, et al
    Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis.
    J Neuroimmunol. 2024;390:578315.
    PubMed     Abstract available
    
    
    
76. LOTFI A, Abbasi M, Karami N, Arghavanfar H, et al
    Effects of treadmill training on myelin proteomic markers and cerebellum morphology in a rat model of cuprizone-induced toxic demyelination.
    J Neuroimmunol. 2024;387:578286.
    PubMed     Abstract available
    
    
    
77. SERAFINI B, Benincasa L, Rosicarelli B, Aloisi F, et al
    EBV infected cells in the multiple sclerosis brain express PD-L1: How the virus and its niche may escape immune surveillance.
    J Neuroimmunol. 2024;389:578314.
    PubMed     Abstract available
    
    
    
78. FRID K, Usmann A, Markovits-Pachter T, Binyamin O, et al
    Granagard administration prolongs the survival of human mesenchymal stem cells transplanted into a mouse model of multiple sclerosis.
    J Neuroimmunol. 2024;389:578313.
    PubMed     Abstract available
    
    
    
79. GALETTA K, Ham AS, Vishnevetsky A, Bhattacharyya S, et al
    Disease modifying therapy in the treatment of tumefactive multiple sclerosis: A retrospective cohort study.
    J Neuroimmunol. 2024;388:578299.
    PubMed     Abstract available
    
    
    January 2024
80. PETERSEN-CHERUBINI CL, Liu Y, Deffenbaugh JL, Murphy SP, et al
    Dysregulated autotaxin expression by T cells in multiple sclerosis.
    J Neuroimmunol. 2024;387:578282.
    PubMed     Abstract available
    
    
    
81. FUJIMORI J, Nakashima I
    Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis.
    J Neuroimmunol. 2024;387:578280.
    PubMed     Abstract available
    
    
    December 2023
82. BAEVA ME, Tottenham I, Koch M, Camara-Lemarroy C, et al
    Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.
    J Neuroimmunol. 2023;387:578268.
    PubMed     Abstract available
    
    
    
83. STAVROGIANNI K, Kitsos DK, Giannopapas V, Chasiotis AK, et al
    Neuropsychological profiles comparison between Multiple Sclerosis patients and Multiple Sclerosis patients with overlapping features of Systemic Lupus Erythematosus.
    J Neuroimmunol. 2023;387:578270.
    PubMed     Abstract available
    
    
    
84. TESFAGIORGIS Y, Kemal EA, Craig HC, Parham KA, et al
    Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed meninges in a chronic model of central nervous system autoimmunity.
    J Neuroimmunol. 2023 Dec 15:578267. doi: 10.1016/j.jneuroim.2023.578267.
    PubMed     Abstract available
    
    
    November 2023
85. FARAJI J, Bettenson D, Yong VW, Metz GAS, et al
    Early life stress aggravates disease pathogenesis in mice with experimental autoimmune encephalomyelitis: Support for a two-hit hypothesis of multiple sclerosis etiology.
    J Neuroimmunol. 2023;385:578240.
    PubMed     Abstract available
    
    
    October 2023
86. LEAL RATO M, Santos M, de Sa J, Ferreira J, et al
    Comorbid autoimmune disorders in people with multiple sclerosis: A retrospective cohort study.
    J Neuroimmunol. 2023;385:578226.
    PubMed     Abstract available
    
    
    September 2023
87. ROSHAN HM, Valadan R, Hosseini SA, Ajami A, et al
    Specific antibodies to EBNA1 epitopes as risk factors for multiple sclerosis, a systematic review.
    J Neuroimmunol. 2023;383:578202.
    PubMed     Abstract available
    
    
    
88. CHHABRA S, Mehan S, Khan Z, Gupta GD, et al
    Matrine mediated neuroprotective potential in experimental multiple sclerosis: Evidence from CSF, blood markers, brain samples and in-silico investigations.
    J Neuroimmunol. 2023;384:578200.
    PubMed     Abstract available
    
    
    
89. GELIBTER S, Pirro F, Saraceno L, Susani E, et al
    Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experience.
    J Neuroimmunol. 2023;383:578199.
    PubMed     Abstract available
    
    
    
90. PERDAENS O, van Pesch V
    MicroRNAs are dysregulated in peripheral blood mononuclear cells in multiple sclerosis and correlate with T cell mediators.
    J Neuroimmunol. 2023;386:578196.
    PubMed     Abstract available
    
    
    August 2023
91. KHAN E, Kagzi Y, Elkhooly M, Surpur S, et al
    Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis.
    J Neuroimmunol. 2023;383:578178.
    PubMed     Abstract available
    
    
    
92. BALAZS I, Horvath A, Heschl B, Khalil M, et al
    Anti-CD20 treatment and neutrophil function in central nervous system demyelinating diseases.
    J Neuroimmunol. 2023;381:578136.
    PubMed     Abstract available
    
    
    
93. SARIN S, Modak N, Sun R, Subei O, et al
    Predicting the final clinical phenotype after the first attack of optic neuritis.
    J Neuroimmunol. 2023;381:578130.
    PubMed     Abstract available
    
    
    
94. SOTTINI A, Quaresima V, Barbaro M, Moiola L, et al
    Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab.
    J Neuroimmunol. 2023;382:578170.
    PubMed     Abstract available
    
    
    
95. BRUNE-INGEBRETSEN S, Hogestol EA, de Rosbo NK, Berg-Hansen P, et al
    Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis.
    J Neuroimmunol. 2023;382:578175.
    PubMed     Abstract available
    
    
    July 2023
96. ADAMEC I, Brecl Jakob G, Rajda C, Drulovic J, et al
    Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centers.
    J Neuroimmunol. 2023;382:578164.
    PubMed     Abstract available
    
    
    
97. PRIEGO M, Noriega L, Kalinin S, Hoffman LM, et al
    Genetic deletion of c-Jun amino-terminal kinase 3 (JNK3) modestly increases disease severity in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2023;382:578152.
    PubMed     Abstract available
    
    
    June 2023
98. ELKJAER ML, Lohse RM, Burton M, Mendoza JP, et al
    Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial.
    J Neuroimmunol. 2023;381:578145.
    PubMed     Abstract available
    
    
    
99. BLASK C, Schulze J, Rumpel S, Susse M, et al
    Modulation of cytokine release from peripheral blood mononuclear cells from multiple sclerosis patients by coenzyme A and soraphen A.
    J Neuroimmunol. 2023;381:578135.
    PubMed     Abstract available
    
    
    
100. SI W, Ni Y, Jiang Q, Tan L, et al
     Nanopore sequencing identifies differentially methylated genes in the central nervous system in experimental autoimmune encephalomyelitis.
     J Neuroimmunol. 2023;381:578134.
     PubMed     Abstract available
     
     
     
101. CARIA P, Pilotto S, D'Alterio MN, Fronza M, et al
     Leukocyte telomere length in women with multiple sclerosis: Comparison with healthy women during pregnancy and puerperium.
     J Neuroimmunol. 2023;381:578137.
     PubMed     Abstract available
     
     
     
102. MICHETTI L, Maffina F, Ravasio R, Barcella V, et al
     Free light chains as a reliable biomarker of intrathecal synthesis in the diagnosis of CNS inflammatory diseases.
     J Neuroimmunol. 2023;379:578091.
     PubMed     Abstract available
     
     
     
103. EL MAHDAOUI S, Husted SR, Hansen MB, Cobanovic S, et al
     Cerebrospinal fluid soluble CD27 is associated with CD8(+) T cells, B cells and biomarkers of B cell activity in relapsing-remitting multiple sclerosis.
     J Neuroimmunol. 2023;381:578128.
     PubMed     Abstract available
     
     
     May 2023
104. MARSTERS C, Nathoo N, Amatto L, Wong R, et al
     Normocomplementemic urticarial vasculitis in a patient with multiple sclerosis on glatiramer acetate.
     J Neuroimmunol. 2023;380:578110.
     PubMed     Abstract available
     
     
     
105. GE A, Sun Y, Kiker T, Zhou Y, et al
     A metabolome-wide Mendelian randomization study prioritizes potential causal circulating metabolites for multiple sclerosis.
     J Neuroimmunol. 2023;379:578105.
     PubMed     Abstract available
     
     
     
106. MANZANO GS, Rice DR, Zurawski J, Jalkh Y, et al
     Familial Mediterranean Fever and multiple sclerosis treated with ocrelizumab: Case report.
     J Neuroimmunol. 2023;379:578099.
     PubMed     Abstract available
     
     
     
107. XUE Y, Zhang L, Guo R, Shao X, et al
     miR-485 regulates Th17 generation and pathogenesis in experimental autoimmune encephalomyelitis through targeting STAT3.
     J Neuroimmunol. 2023;379:578100.
     PubMed     Abstract available
     
     
     April 2023
108. MULLER-MINY L, Heming M, Lautwein T, Ruck T, et al
     Alemtuzumab treatment exemplifies discordant immune effects of blood and cerebrospinal fluid in multiple sclerosis.
     J Neuroimmunol. 2023;378:578088.
     PubMed     Abstract available
     
     
     
109. VACARAS V, Muresanu DF, Buzoianu AD, Nistor C, et al
     The role of multiple sclerosis therapies on the dynamic of human gut microbiota.
     J Neuroimmunol. 2023;378:578087.
     PubMed     Abstract available
     
     
     March 2023
110. ABBADESSA G, Miele G, Cavalla P, Valentino P, et al
     Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab.
     J Neuroimmunol. 2023;378:578072.
     PubMed     Abstract available
     
     
     
111. FERREIRA F, Ferreira D, Guimaraes J, Soares-Dos-Reis R, et al
     Recurrent encephalopathy associated with pegylated beta-interferon treatment.
     J Neuroimmunol. 2023;376:578037.
     PubMed     Abstract available
     
     
     
112. PALACIO PL, Pleet ML, Reategui E, Magana SM, et al
     Emerging role of extracellular vesicles in multiple sclerosis: From cellular surrogates to pathogenic mediators and beyond.
     J Neuroimmunol. 2023;377:578064.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum